1Giovanni de Simone,Kristian Wachten,Vittorio palmieri,et al.Body build and risk of cardiovascular events in hypertension andleft ventricular hypertrophy(LIFE)study[].Circulation.2005
2Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomized placebo-controlled trial[].The Lancet.2002
3Sever PS,Dahlof B,Poulter NR,et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomise[].The Lancet.2003
4Guidelines Subcommittee.1999World Health Organization-In-ternationa-lSociety of Hypertension Guidelines for the Manag-ement of Hypertension[].Journal of Hypertension.1999
5Michel E Safar,,Albert Fournier.Letter by safar and Fournierregarding article,"Differential impact of blood pressure lower-ing drugs on central aortic pressure and clinical outcome:principal result of the conduit artery function evaluation(CAFé)study"[].Circulation.2006
6Wright JC,,Looney SW.Prevalence of positive osler’s maneu-ver in 3387 persons screened for the systolic hypertension inthe elderly program(SHEP)[].Journal of Human Hypertension.1997
7Hansson L,Zanchetti A,Carruthers SG,et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension[].The Lancet.1998
8Pepine CJ,Handberg-Thurmond E,Marks RG,et al.Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension[].Journal of the American College of Cardiology.1998
